原位雜合反應市場規模、佔有率和成長分析：按技術、產品、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球原位雜合反應(ISH) 市場價值為 25.2 億美元，預計到 2025 年將成長至 27.5 億美元，到 2033 年將成長至 55.2 億美元，在預測期（2026-2033 年）內複合年成長率為 9.12%。

全球原位雜合反應(ISH) 市場正經歷顯著成長，這主要得益於對精準分子診斷（尤其是腫瘤學領域）日益成長的需求，從而拓展了個人化醫療的選擇範圍。 ISH 使臨床醫生能夠識別完整細胞內的特定核酸序列，進而根據組織中觀察到的基因變異制定標靶治療方案。 RNA-ISH 試劑盒獲得監管部門批准後，ISH 的應用範圍向臨床病理學領域擴展，這與空間轉錄組學的更廣泛趨勢相輔相成，提高了研究和商業性可行性。此外，數位成像和人工智慧分析技術的進步正在革新 ISH，將玻片檢查結果轉化為可量化的生物標記，並促進檢查室自動化。這種整合透過提高一致性、降低成本和提升檢體處理能力，推動了整體市場成長，並擴大了 ISH 在臨床診斷和藥物研發中的應用範圍。

全球原位雜合反應市場按技術、產品、應用、最終用戶和地區進行細分。依技術分類，市場分為螢光原位雜合反應(FISH)、顯色原位雜合反應(CISH)、銀敏原位雜合反應(SISH) 和 RNAscope（單分子 FISH）。依產品分類，市場分為儀器、試劑盒和軟體。按應用分類，市場分為癌症診斷（包括 HER2 和 ALK 檢測）、產前診斷和感染疾病檢測。依最終用戶分類，市場分為醫院、研究機構和診斷檢查室。按地區分類，市場分析涵蓋北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球原位雜合反應市場成長要素

全球原位雜合反應市場的發展主要得益於現代平台技術的進步，這些平台能夠提供更高的靈敏度和更強大的多重檢測能力。這些創新使得研究人員能夠在單一組織切片中識別多個核酸標靶，從而加速發現過程並減少實驗重複次數。此類技術進步尤其有利於檢測低表現的傳訊RNA，並拓展了其在腫瘤學、神經科學和感染疾病等領域的應用範圍。因此，越來越多的實驗室開始採用這些先進的解決方案來提高數據品質並加快研究進程。此外，簡化的工作流程減輕了工作人員的負擔，從而促進了學術機構和工業界對這些技術的廣泛應用。

全球原位雜合反應市場的限制因素

由於專有探針、酵素和檢測試劑盒高成本，全球原位雜合反應市場面臨巨大的限制。這對於許多預算有限或核准流程繁瑣的研究機構而言，無疑是一項沉重的財務挑戰。不斷上漲的成本使得常規原位雜合反應難以進行，迫使各機構尋求更具成本效益的替代方案，例如免疫組織化學和基於PCR的檢測方法。這種財務壓力阻礙了市場成長，尤其是在學術領域，在新興經濟體中更為顯著，因為這些地區的資金往往優先用於更廣泛、成本更低的調查方法，最終導致原位雜合反應市場的整體成長放緩。

全球原位雜合反應市場趨勢

在全球原位雜合反應（ISH）市場中，分子病理學的進步推動了其與診斷流程的顯著整合。隨著越來越多的實驗室將ISH應用於常規檢測，其在區分疾病亞型和指南標靶治療的作用日益關鍵。這項轉變的促進因素包括臨床醫生對高空間解析度生物標記數據的需求不斷成長，以及多探針組的引入提高了操作效率。因此，ISH正從小眾研究應用走向主流臨床診斷，透過提高診斷可靠性並與個人化醫療的更廣泛趨勢相契合，確立其在精準診斷中的基石地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球原位雜合反應市場規模：依技術分類

• FISH（螢光雜合反應）
• CISH（顯色原位雜合技術）
• SISH（銀敏化原位雜合技術）
• RNAscope（單分子FISH）

全球原位雜合反應市場規模：依產品分類

• 裝置
• 試劑和試劑盒
• 軟體

全球原位雜合反應市場規模：按應用領域分類

• 癌症診斷（HER2、ALK）
• 產前診斷
• 感染疾病

全球原位雜合反應市場規模：依最終用戶分類

• 醫院
• 研究機構
• 診斷實驗室

全球原位雜合反應市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Abbott Molecular（Vysis FISH）
• Roche Diagnostics（Ventana）
• Agilent Technologies
• Thermo Fisher Scientific
• Bio-Techne（Advanced Cell Diagnostics）
• Leica Biosystems（Danaher）
• Cytovision（Leica）
• MetaSystems Group
• Miltenyi Biotec
• PerkinElmer
• Ikonisys Inc.
• Zytovision（BioView）
• Empire Genomics
• Creative Bioarray
• BioView Ltd.
• Quantase
• Ortho Clinical Diagnostics
• Hologic Inc.
• Genoptix（Novartis）
• LabCorp（Dianon Pathology）

結論與建議

Global In Situ Hybridization Market size was valued at USD 2.52 Billion in 2024 and is poised to grow from USD 2.75 Billion in 2025 to USD 5.52 Billion by 2033, growing at a CAGR of 9.12% during the forecast period (2026-2033).

The global in situ hybridization (ISH) market is witnessing significant growth driven by an increasing demand for precise molecular diagnostics, particularly in oncology, enabling personalized treatment options. ISH allows clinicians to identify specific nucleic acid sequences within intact cells, facilitating targeted therapy decisions based on genetic changes observed in tissues. A shift towards clinical pathology, aided by regulatory approvals for RNA-ISH kits, complements the broader trend in spatial transcriptomics, enhancing research and commercial viability. Additionally, advancements in digital imaging and AI analytics are transforming ISH by converting slide results into quantifiable biomarkers, promoting automation in laboratories. This integration boosts consistency, reduces costs, and enhances sample throughput, thereby expanding ISH's application in clinical diagnostics and pharmaceutical research, driving overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global In Situ Hybridization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global In Situ Hybridization Market Segments Analysis

The global in situ hybridization market is segmented based on technology, product, application, end-user, and region. By technology, the market is categorized into Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), Silver-Enhanced In Situ Hybridization (SISH), and RNAscope (Single-Molecule FISH). Based on product, the market is divided into Instruments, Reagents & Kits, and Software. By application, the market is segmented into Cancer Diagnostics (including HER2 and ALK testing), Prenatal Diagnosis, and Infectious Disease Detection. Based on end-user, the market is classified into Hospitals, Research Institutes, and Diagnostic Laboratories. Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Driver of the Global In Situ Hybridization Market

The global in situ hybridization market is being propelled by advancements in modern platforms that offer enhanced sensitivity and improved multiplexing capabilities. These innovations enable researchers to identify multiple nucleic acid targets within a single tissue slice, facilitating faster discovery processes and minimizing the need for repeated experiments. Such technological enhancements are particularly beneficial for detecting low abundance messenger RNA, broadening the application spectrum across fields like oncology, neuroscience, and infectious diseases. Consequently, laboratories are increasingly opting for these superior solutions to achieve higher data quality and expedite their research efforts. Additionally, a more efficient workflow reduces operator fatigue, leading to wider adoption across both academic and industrial settings.

Restraints in the Global In Situ Hybridization Market

The Global In Situ Hybridization market faces significant restraints due to the high costs associated with proprietary probes, enzymes, and detection kits, which can pose financial challenges for many research institutions operating on limited budgets or facing stringent approval processes. These elevated expenses make routine in situ hybridization less accessible, prompting laboratories to consider alternative, more cost-effective approaches such as immunohistochemistry or PCR-based assays. This financial pressure hampers market growth, particularly in academic environments, and is amplified in emerging economies where funding is often prioritized for broader, lower-cost methodologies, ultimately causing a deceleration in the overall growth trajectory of the in situ hybridization market.

Market Trends of the Global In Situ Hybridization Market

The Global In Situ Hybridization (ISH) market is experiencing a significant trend toward integration within diagnostic workflows, driven by advancements in molecular pathology. As laboratories increasingly adopt ISH for routine testing, its role in distinguishing disease subtypes and guiding targeted therapies becomes more prominent. This shift is fueled by clinicians' rising demand for spatially resolved biomarker data, coupled with the introduction of multiplexed probe sets that enhance operational efficiency. Consequently, ISH is transitioning from niche research applications into mainstream clinical diagnostics, reinforcing diagnostic confidence and aligning with the broader movement toward personalized medicine, positioning ISH as a cornerstone of precision diagnostics.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global In Situ Hybridization Market Size by Technology & CAGR (2026-2033)

• Market Overview
• FISH (Fluorescence In Situ Hybridization)
• CISH (Chromogenic ISH)
• SISH (Silver-Enhanced ISH)
• RNAscope (Single-Molecule FISH)

Global In Situ Hybridization Market Size by Product & CAGR (2026-2033)

• Market Overview
• Instruments
• Reagents & Kits
• Software

Global In Situ Hybridization Market Size by Application & CAGR (2026-2033)

• Market Overview
• Cancer Diagnostics (HER2, ALK)
• Prenatal Diagnosis
• Infectious Disease

Global In Situ Hybridization Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Research Institutes
• Diagnostic Labs

Global In Situ Hybridization Market Size & CAGR (2026-2033)

• North America (Technology, Product, Application, End-User)
  • US
  • Canada
• Europe (Technology, Product, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Product, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Product, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Product, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abbott Molecular (Vysis FISH)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Ventana)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne (Advanced Cell Diagnostics)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytovision (Leica)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MetaSystems Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Miltenyi Biotec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ikonisys Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zytovision (BioView)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Empire Genomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Bioarray
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioView Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quantase
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ortho Clinical Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genoptix (Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LabCorp (Dianon Pathology)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations